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Abstract
Background: Randomised controlled trials have provided conflicting results regarding procedural and clinical outcomes 
of thrombus aspiration combined with percutaneous coronary intervention, when compared with primary percutaneous 
coronary intervention alone in patients with acute coronary syndromes.
Methods: Acute coronary syndrome patients referred for coronary angiography to four Swiss university hospitals 
between 2009 and 2012 were enrolled in the SPUM–ACS cohort. At the discretion of the interventional cardiologist, 
patients underwent thrombus aspiration with percutaneous coronary intervention or percutaneous coronary 
intervention alone. Procedural success was defined as post-procedural thrombolysis in myocardial infarction III flow 
in the infarct-related artery. Serial changes in high-sensitivity troponin T (ΔhsTnT) and adjudicated 30 days (1 year) 
clinical events defined as the composite of cardiac death, recurrent myocardial infarction or clinically indicated coronary 
revascularisation were assessed.
Results: Among 1641 patients, 777 (47.4%) had angiographic evidence of coronary thrombus. Patients were categorised 
into thrombus aspiration with percutaneous coronary intervention (n=663) or percutaneous coronary intervention 
alone (n=114). ST-segment elevation myocardial infarction (STEMI) patients more often received thrombus aspiration 
with percutaneous coronary intervention (87.8%) than non-STEMI patients (73.5%), P<0.001. Procedural success was 
not different in thrombus aspiration with percutaneous coronary intervention compared with percutaneous coronary 
intervention alone (93.8% vs. 90.7%, P=0.243). ΔhsTnT was similar in STEMI patients (3.09±4.52 vs. 2.19±4.92 µg/l, 
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P=0.086) as was clinical outcome in the entire cohort at 30 days (2.9% vs. 3.6%, P=0.76) and 1 year (7.2% vs. 5.3%, 
P=0.55) regardless of whether thrombus aspiration was used during primary percutaneous coronary intervention or not.
Conclusions: In this real-world acute coronary syndrome cohort, patients treated by thrombus aspiration with 
percutaneous coronary intervention showed no difference in the restoration of coronary blood flow compared with 
percutaneous coronary intervention alone immediately after the procedure. Furthermore, ΔhsTnT and clinical outcomes 
at either 30 days or 1 year were similar between thrombus aspiration with percutaneous coronary intervention or 
percutaneous coronary intervention alone.
Clinical Trials Registration: SPUM–ACS cohort NCT01000701
Keywords
Acute coronary syndromes, percutaneous coronary intervention, thrombus aspiration, TIMI flow, biomarkers, clinical 
outcome
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Introduction
Thrombus aspiration (TA) has routinely been used in recent 
years as an adjunct to primary percutaneous coronary inter-
vention (PCI) in acute coronary syndrome (ACS) patients 
with angiographic evidence of intracoronary thrombi, in 
order to restore perfusion, prevent peripheral embolisation 
and potentially microvascular obstruction (MVO) and no-
reflow. MVO was recently identified as an independent 
predictor of adverse clinical events in patients with 
ST-segment elevation myocardial infarction (STEMI).1 
Several randomised controlled trials have been performed 
comparing TA combined with PCI or primary PCI alone in 
patients with STEMI2–7 and non-ST-segment elevation 
myocardial infarction (NSTEMI),8 respectively. The 
TAPAS trial demonstrated that manual aspiration of throm-
botic material can be performed in the large majority of 
patients presenting with STEMI, and that reperfusion of the 
ischaemic myocardium as assessed by myocardial blush 
grade can be improved compared with primary PCI alone.2 
Of note, ST-segment elevation and ST-segment deviation 
normalised faster than with PCI alone.2 Furthermore, a 
follow-up study of the TAPAS trial showed that the improve-
ment in myocardial reperfusion was associated with a 
reduced rate of cardiac death and non-fatal myocardial 
infarction (MI) at 1 year.3 In contrast to the above, in the 
INFUSE–AMI trial infarct size as assessed by cardiac mag-
netic resonance imaging at 30 days was not reduced by TA 
with PCI compared with PCI alone in patients with anterior 
STEMI.4 However, the TASTE trial showed that in STEMI 
patients, TA with PCI compared with PCI alone did not 
reduce all-cause mortality at 30 days,5 nor the prespecified 
secondary endpoint of all-cause mortality at 1 year.6 Finally, 
the TOTAL trial also enrolling STEMI patients confirmed 
the results of the TASTE trial that TA with PCI compared 
with PCI alone did not alter the composite endpoint of car-
diovascular death, recurrent MI, cardiogenic shock, or New 
York Heart Association (NYHA) class IV heart failure 
within 180 days.7 Interestingly, in NSTEMI patients, the 
TATORT–NSTEMI trial showed that TA with PCI did not 
reduce MVO defined as the primary endpoint compared 
with PCI alone.8
In this context, it was the primary aim of this study to 
assess the prevalence of TA during primary PCI, proce-
dural success, change in serial troponin T levels and clini-
cal outcomes defined as the composite of cardiac death, 
recurrent MI and clinically indicated coronary revascu-
larisation in a cohort of STEMI/NSTEMI patients in a 
real-world setting of a prospective cohort recruited at four 
Swiss university hospitals.
Materials and methods
Patient population
The Special Program University Medicine Acute Coronary 
Syndromes and Inflammation (SPUM–ACS) was estab-
lished by four Swiss university hospitals (Bern, Geneva, 
Lausanne and Zurich) to prospectively recruit and analyse 
a real-world cohort of patients with ACSs.9–11 Consecutive 
patients with a diagnosis of ACS that underwent coronary 
angiography were enrolled between December 2009 and 
October 2012. Inclusion criteria comprised patients of both 
genders, aged 18 years and older, presenting within 5 days 
(preferably within 72 hours) after pain onset with a main 
diagnosis of STEMI, NSTEMI or unstable angina. Enrolled 
patients had symptoms compatible with angina pectoris 
(chest pain, dyspnoea) and fulfilled at least one of the 
following criteria: (a) ECG changes, such as persistent 
ST-segment elevation or depression, T-inversion or 
dynamic ECG changes or new left bundle branch block; (b) 
evidence of positive (predominantly conventional) tro-
ponin by local laboratory reference values (with a rise and/
or fall in serial troponin levels); (c) known coronary artery 
disease specified by its status after MI, coronary artery 
bypass graft, or PCI or newly documented 50% or greater 
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stenosis of an epicardial coronary artery during the initial 
catheterisation. Exclusion criteria comprised severe physi-
cal disability, inability to comprehend the study, or less than 
1 year of life expectancy for non-cardiac reasons. The study 
was approved by the local ethical committees and all 
patients gave written informed consent in compliance with 
the Declaration of Helsinki as listed under ClinicalTrials.
gov number NCT01000701.
Angiographic parameters
Prespecified angiography case report forms were used for 
each patient at index coronary angiography to ascertain 
angiographic evidence of coronary thrombus adjacent to 
the culprit lesion, and also to establish whether TA was 
performed with pertinent documentation of thrombolysis 
in myocardial infarction (TIMI) flow12 before and after 
PCI. Procedural success was defined as post-procedural 
TIMI-III flow in the infarct-related artery. Peri-procedural 
medications administered were ascertained and all data 
were entered into an electronic database.
Serial change in high-sensitivity troponin T
Blood was drawn at the time of index coronary angiogra-
phy (high-sensitivity troponin T (hsTnT1)) and 12–24 
hours later (hsTnT2). Serum aliquots were frozen at −80°C 
after centrifugation at 2700g for 10 minutes at room tem-
perature until serial measurement (no prior freeze–thaw 
cycles) in the Zurich core laboratory. Aliquots were meas-
ured, blinded to patient data by means of numbered ID 
codes, to determine the concentration of hsTnT in one 
serum aliquot per patient using an electrochemilumines-
cence immunoassay analysed on a Cobas e 602 reader 
(Roche Diagnostics, Mannheim, Germany), with assay 
characteristics as reported by the manufacturer.
Clinical endpoints
Follow-up was performed at 30 days (phone call) and at 1 
year (clinical visit) with events adjudicated by three inde-
pendent experts using prespecified event adjudication 
forms. Major adverse cardiac events (MACE) were defined 
as the composite of cardiac death, non-fatal recurrent MI 
(according to the universal definition comprising both 
spontaneous and peri-procedural MI)13 or clinically indi-
cated coronary revascularisation.
Clinical risk score calculation
The Global Registry of Acute Coronary Events (GRACE) 
risk score was used to calculate both in-hospital and long-
term predictions of mortality and to assess the degree of 
disease severity in patients included in the current study. 
The GRACE risk criteria used to assess the score for 
in-hospital mortality comprised age, heart rate, systolic 
blood pressure, initial serum creatinine, Killip class, 
cardiac arrest on admission, elevated cardiac markers 
(conventional troponins as per local laboratories) and 
ST-segment deviation.14 The GRACE risk criteria used to 
calculate the score for long-term mortality comprised age, 
heart rate, systolic blood pressure, initial serum creatinine, 
history of congestive heart failure, history of MI, elevated 
cardiac markers (conventional troponins as per local labo-
ratories), ST-segment depression and no in-hospital PCI.15 
The GRACE risk scores (short and long-term) were calcu-
lated using a programme written in Stata statistical soft-
ware (version 13; Stata Corp, College Station, TX, USA) 
and we used the standard scoring of the GRACE risk score 
as mentioned in the reference publications.14,15
Statistical analyses
The aim of the study was to assess the effect of TA with PCI 
in patients with angiographic documentation of coronary 
thrombus. Among these, we categorised patients based 
on whether TA with PCI or PCI alone was performed. 
Throughout, results are reported at the patient level (lesion-
level analysis is available in the supplementary material).
The clinical characteristics of each group are presented 
for baseline continuous variables as means with standard 
deviations and P values from t-tests. Categorical variables 
are shown as counts with percentages and P values from 
χ2 or Fisher’s exact tests. P values for procedural success 
are derived from logistic regression. We compared medi-
ans of ΔhsTnT, with P values from the Wilcoxon rank-
sum test.
Odds ratios (ORs) and 95% confidence intervals (CIs) 
were estimated using logistic regression with P values from 
the Wald test.
Clinical outcomes were analysed, censoring patients at 
30 days (data for 1-year follow-up are shown in the sup-
plementary material), at death, or at last valid contact date 
using Cox’s regression. For procedural success and clini-
cal outcomes we used inverse propensity score estimators 
to obtain covariate adjusted results. To calculate the pro-
pensity score, we included in a logistic regression (with 
outcome receiving TA with PCI) baseline variables which 
had a P value less than 0.2: age (⩾75 vs. <75 years), 
weight (<60 vs. ⩾60 kg), renal failure (<60 vs. ⩾60 glo-
merular filtration rate), STEMI (yes, no; no refers to 
NSTEMI), stent deployment (‘stenting’) and balloon angi-
oplasty (‘ballooning’) classified as yes/no. The inverse 
probability of treatment weights (IPTW) were calculated 
as the inverse of the probability of receiving the treatment 
actually received.16 Then we conducted a logistic regres-
sion (for procedural success) and Cox’s regressions (for 
the clinical outcomes) weighted by IPTW with robust 
standard errors for obtaining 95% CIs. Furthermore, we 
stratified these analyses according to specified subgroups 
of baseline variables as mentioned above and also dichot-
omised pre-procedural TIMI flow (0/I vs. II/III).
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P values for interactions were obtained with approxi-
mate χ2 tests for interaction across subgroups, i.e. from 
logistic regression (procedural success) or Cox’s regression 
(clinical outcomes). Two sided P values were reported 
throughout and P values smaller than 0.05 were considered 
statistically significant. Statistical analyses were performed 
using Stata statistical software (version 14; Stata Corp, 
College Station, TX, USA).
Results
Prevalence of TA
Among 1641 patients with either STEMI or NSTEMI, 777 
patients (47.4%) had angiographic evidence of coronary 
thrombus (Figure 1) and were treated by TA with PCI 
(n=663) or PCI alone (n=114). Overall, in both STEMI 
(641) and NSTEMI patients (136), TA with PCI was per-
formed more frequently (P<0.001) than PCI alone 87.8%
(563/641) versus 73.5% (100/136), respectively (Table 1).
The baseline characteristics of the two patient groups indi-
cate that PCI with deployment of a stent and the use of gly-
coprotein IIb/IIIa antagonists or bivalirudin were more
frequent in patients treated by TA with PCI compared with
PCI alone. In turn, PCI with balloon angioplasty alone and
the use of proton pump inhibitors were found more fre-
quently in patients treated by PCI alone compared with TA
with PCI (Table 1).
Post-procedural coronary blood flow
Procedural success was defined as post-procedural TIMI-
III flow in the infarct-related artery. Procedural success 
was similar in patients treated by TA with PCI compared 
with PCI alone (93.8% vs. 90.7%, P=0.243; Table 2). 
Stratified and IPTW adjusted analysis of procedural suc-
cess in all lesions yielded similar results across major sub-
groups with an overall OR of 0.73 (95% CI 0.34–1.58, 
P=0.429; Figure 2). Restoration of coronary blood flow 
was obtained in both groups despite a higher rate of vessel 
occlusion (TIMI-0 or I flow) prior to intervention in 
patients treated by TA with PCI compared with PCI alone 
(93.8% vs. 90.7%, P=0.243; Table 2). These results were 
similar when analysed on a lesion level (Supplementary 
Table 1).The rate of direct stenting in the lesion was more 
frequent in patients treated by TA with PCI compared with 
patients treated by PCI alone (34.9% vs. 24.5%, P=0.021) 
(Supplementary Table 1).
Serial change in high-sensitivity troponin T
Procedural success (restoration of TIMI-III flow) and 
hsTnT measurements from baseline (hsTnT1) and 12–24 
hours later (hsTnT2) were available in 541 patients. The 
absolute change in concentration of hsTnT (ΔhsTnT = 
hsTnT2 – hsTnT1), median ± interquartile range was 
similar between patients treated by TA with PCI and 
patients treated by PCI alone, for STEMI patients 
(3.09±4.52 vs. 2.19±4.92 µg/l, P=0.086; Table 3). In 
patients with STEMI stratified by time of chest pain onset 
to first blood draw the change in the level of hsTnT was 
similar in patients treated by TA with PCI compared with 
PCI alone, both in early and late presenters (Figure 3, 
Supplementary Table 2).
Clinical outcome
Follow-up data until 30 days were complete in 99.7% 
of patients treated by TA with PCI and in 99.1% of 
patients treated by PCI alone (Figure 1). Individual 
adjudicated events are shown in Supplementary Table 3. 
The composite endpoint at 30 days (MACE) occurred in 
2.9% (19/663) of patients treated by TA with PCI and 
3.6% (4/114) of patients treated by PCI alone (P=0.76). 
For 30 days (MACE) stratified IPTW adjusted analysis of 
all 777 patients with the presence of coronary thrombus 
and undergoing interventional treatment showed similar 
clinical outcomes between patients treated by TA with 
PCI and patients treated by PCI alone across subgroups 
with an overall hazard ratio (HR) of 1.03 (95% CI 0.31–
.43, P=0.968; Figure 4). At 1 year the composite end-
point was found in 7.2% (48/663) of patients treated by 
TA with PCI and 5.3% (6/114) of patients treated by 
PCI alone (P=0.55) (Supplementary Table 3). Stratified 
IPTW adjusted analysis for 1 year MACE showed no 
difference in clinical outcome across major subgroups 
(Supplementary Figure 1).
Discussion
Our study shows that in a real-world prospective contem-
porary ACS cohort: (a) patients treated by TA during pri-
mary PCI showed no difference in restoration of coronary 
blood flow after the procedure compared with those treated 
with PCI alone; (b) the absolute change in hsTnT as a 
measure of infarct size was similar between groups, as were 
(c) the clinical short and long-term outcomes.
Corroborating prior data from a large Japanese registry
reporting a 63.3% rate of TA during primary PCI in STEMI 
patients,17 we found a high rate of 87.8% (563/641) of TA 
in STEMI patients. Conversely, 73.5% (100/136) of the 
NSTEMI patients enrolled in the present cohort were 
treated by TA with PCI, in contrast to data from a subanaly-
sis of the ACUITY trial,18 in which the rate of TA with PCI 
was 9.4% in NSTEMI patients presenting with an angio-
graphically visible thrombus.
Of note, restoration of TIMI-III flow (as a reflection of 
procedural success) was achieved in 93.8% of the patients in 
whom TA was performed during primary PCI (and in 90.7% 
of the patients by the use of PCI alone), also corroborating 
findings from the randomised TAPAS2 and INFUSE–AMI4 
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Figure 1. Study flow: flow chart shows the distribution of STEMI/NSTEMI patients with available baseline biomarker data (hsTnT1) 
and comprehensive procedural data. (Data analysed n=777).
trials reporting success rates of 86% and 92.6% in STEMI 
patients, respectively. Furthermore, and in line with data 
from the TASTE, TOTAL and NSTEMI–TATORT5,7,8 tri-
als, primary stenting was more frequently performed in 
patients treated by TA compared with those that were 
treated by PCI alone.
Despite improved restoration of coronary blood flow 
upon TA with PCI, serial measurement of hsTnT as 
an index of infarct size revealed similar changes in 
concentration both for patients treated by TA with PCI 
or PCI alone, respectively. This extends the results of 
the TATORT–NSTEMI trial8 to a real-world ACS cohort. 
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Table 1. Baseline characteristics.
Thrombus present P value
TA + PCI PCI alone
Total number of patients n=663 n=114
Age (years) n=663, 60.99±12.15 n=114, 61.99±13.55 0.422
 ⩾75 years n=663, 103 (15.5%) n=114, 24 (21.1%) 0.169
Gender (female) n=663, 118 (17.8%) n=114, 23 (20.2%) 0.514
Weight (kg) n=654, 80.69±14.94 n=111, 77.91±14.09 0.068
<60 kg (yes) n=654, 34 (5.2%) n=111, 11 (9.9%) 0.077
 Body mass index (kg/m²) n=653, 26.95±4.09 n=111, 26.72±4.26 0.597
Medical history
Diabetes mellitus n=663, 74 (11.2%) n=114, 17 (14.9%) 0.269
 Hypertension n=663, 323 (48.7%) n=114, 56 (49.1%) 1.000
 Hypercholesterolemia n=663, 382 (57.6%) n=114, 69 (60.5%) 0.608
Current smoker n=655, 290 (44.3%) n=112, 45 (40.2%) 0.471
Family history of CAD n=654, 163 (24.9%) n=114, 22 (19.3%) 0.235
Renal failurea n=661, 74 (11.2%) n=114, 6 (5.3%) 0.065
History of stroke or TIA n=663, 18 (2.7%) n=114, 3 (2.6%) 1.000
Previous myocardial infarction n=662, 62 (9.4%) n=114, 15 (13.2%) 0.234
Previous PCls n=663, 84 (12.7%) n=113, 14 (12.4%) 1.000
Previous CABG n=663, 21 (3.2%) n=114, 4 (3.5%) 0.776
Clinically relevant valvular disease n=663, 8 (1.2%) n=114, 1 (0.9%) 1.000
Clinical presentation  Pearson χ2 (1)=18.33, P<0.001
 STEMI n=663, 563 (84.9%) n=114, 78 (68.4%) –
 NSTEMI n=663, 100 (15.1%) n=114, 36 (31.6%) –
Killip class
 I n=663, 553 (84.2%) n=114, 94 (82.4%) 0.679
 II n=663, 66 (10.0%) n=114, 18 (15.8%) 0.074
 III n=663, 13 (2.0%) n=114, 1 (0.9%) 0.706
 IV n=663, 25 (3.8%) n=114, 1 (0.9%) 0.157
Systolic blood pressure (mmHg) n=659, 127.2±23.7 n=114, 128.4±22.7 0.603
Heart rate (beats per minute) n=660, 76.7±17.05 n=114, 77.54±16.87 0.632
Index procedure
 Stentingb n=663, 641 (96.7%) n=114, 102 (89.5%) 0.002
Any drug-eluting stent n=663, 483 (72.9%) n=114, 79 (69.3%) 0.430
Any bare-metal stent n=663, 170 (25.6%) n=114, 26 (22.8%) 0.561
 Ballooning n=663, 53 (8.0%) n=114, 18 (15.8%) 0.013
Pre-procedural medication
No P2Y12 inhibitor 18 (2.7%) 3 (2.6%) 0.960
 Clopidogrel 299 (45.1%) 55 (48.3%) 0.533
 Prasugrel 164 (24.7%) 21 (18.4%) 0.155
 Ticagrelor 14 (2.1%) 2 (1.8%) 0.804
Mixture of (P2Y12) inhibitors 168 (25.3%) 33 (28.9%) 0.417
Glycoprotein IIb/IIIa inhibitors 283 (42.7%) 30 (26.3%) <0.001
Unfractionated heparin 638 (96.2%) 110 (96.5%) 0.557
 Bivalirudin 58 (8.7%) 2 (1.8%) 0.010
Baseline medication
Proton-pump inhibitor n=660, 71 (10.8%) n=113, 20 (17.7%) 0.040
 Oral anticoagulation n=660, 18 (2.7%) n=113, 2 (1.8%) 0.754
GRACE risk score
 In-hospital n=663, 147.51±33.48 n=114, 144.29±33.46 0.343
 Long-term n=663, 118.11±25.48 n=114, 119.23±27.84 0.669
Depicted are counts (%) or means ± SDs.
a Based on creatinine-estimated glomerular filtration rate clearance of <60 mL/min/1.73 m², using the modification of diet in renal disease (MDRD) formula.
bMix of drug-eluting stents and bare-metal stents possible.
CABG: coronary artery bypass graft; CAD: coronary artery disease; LMWH: low-molecular weight heparin; TA: thrombus aspiration; PCI: 
percutaneous coronary intervention; TIA: transient ischaemic attack; GRACE: Global Registry of Acute Coronary Events.
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Table 2. Procedural success and TIMI flow.
Thrombus present P value
TA + PCI PCI alone
Number of patients with PCIa n=648 n=107
TIMI flow pre-procedureb
 0/I 528 (81.5%) 68 (63.6%) <0.001
 II 67 (10.3%) 17 (15.9%) 0.106
 III 53 (8.2%) 22 (20.6%) <0.001
TIMI flow post-procedureb
 0/I 12 (1.9%) 3 (2.8%) 0.534
 II 28 (4.3%) 7 (6.5%) 0.334
 IIIc 608 (93.8%) 97 (90.7%) 0.243
a Only analysed for patients with pre- and post-procedural TIMI flow data available (n=755).
b Worst TIMI flow per patient reported.
c Procedural success was defined as post-procedural TIMI-III flow in the infarct-related artery.
TA: thrombus aspiration; PCI: percutaneous coronary intervention.
Figure 2. Inverse probability of treatment weighting (IPTW) adjusted analysis of procedural success across major subgroups 
according to baseline characteristics. aOnly analysed for patients with pre- and post-procedural TIMI flow data available (n=755). 
bRenal failure is defined as creatinine-estimated glomerular filtration rate clearance of <60 mL/min/1.73 m², using the modification 
of diet in renal disease (MDRD) formula. cNo refers to NSTEMI patients.
Table 3. Serial change in high-sensitivity troponin T in patients with procedural success.
Thrombus present P value
TA + PCI PCI alone
Number of patients with PCIa n=472 n=69
Level of hsTnT in ΔT (µg/l)b
 STEMI n=402 n=45
  Mean±SD 4.25 ± 4.36 3.07 ± 3.28 0.079
  Median±IQR 3.09 ± 4.52 2.19 ± 4.92 0.086
 NSTEMI n=70 n=24
  Mean±SD 1.06 ± 1.64 0.29 ± 0.61 0.027
  Median±IQR 0.45 ± 1.46 0.20 ± 0.67 0.012
a Only analysed for patients with pre- and post-procedural TIMI flow data and measurement of hsTnT2 available. Patients with no improvement in TIMI flow were 
discarded from this analysis.
b ΔhsTnT = hsTnT2 – hsTnT1.
TA: thrombus aspiration; PCI: percutaneous coronary intervention; IQR: interquartile range.
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Importantly, stratification by the time interval of chest 
pain onset to first blood draw in patients with STEMI 
yielded similar results, suggesting a true disparity of 
blood flow restoration and infarct size under these 
conditions.
Corresponding to troponin data, rates of MACE at 30 
days and 1 year were similar in patients that were treated 
by TA during primary PCI or by PCI alone. These out-
come data generated by our sizeable real-world cohort are 
in line with the results obtained from large randomised 
trials carried out in STEMI5,7 and NSTEMI8 patients, 
respectively. A recent meta-analysis of randomised trials 
reporting mortality as a primary outcome (either all-cause 
or cardiovascular) similarly concluded that, contrary to 
the expectations of many interventionalists, TA with PCI 
does not reduce the rates of death, nor secondary end-
points, such as reinfarction, stent thrombosis or stroke.19 
Furthermore, our data extend registry data from STEMI 
patients20,21 to patients with NSTEMI/STEMI.
Limitations
The current study reports observational data from patients 
in the SPUM–ACS cohort, in which ACS patients were 
prospectively enrolled in four Swiss university hospitals. 
In our study, TA was performed at the discretion of the 
treating interventional cardiologist. This design differs 
from interventional trials in which patients were ran-
domly assigned to TA with PCI or PCI alone. Nevertheless, 
the SPUM–ACS cohort provides real-world data which 
add important information for clinical practice.
Figure 4. Inverse probability of treatment weighting (IPTW) adjusted analysis of clinical outcome (major adverse cardiac events 
(MACE)) at 30 days across major subgroups according to baseline characteristics (n=777). aRenal failure is defined as creatinine-
estimated glomerular filtration rate clearance of <60 mL/min/1.73 m², using the modification of diet in renal disease (MDRD) 
formula. bSTEMI (yes, no; no refers to NSTEMI). cPre-procedural TIMI flow: analysed only for patients with pre-procedural TIMI 
flow data available (n=755).
Figure 3. Serial change in high-sensitivity troponin T (hsTnT) 
levels (ΔhsTnT = hsTnT2 – hsTnT1) in STEMI patients with 
procedural success stratified by the onset of chest pain to first 
blood draw (n=403).
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Among the endpoints analysed, TIMI flow was assessed 
by experienced interventional fellows, which may contain a 
certain level of variability unlike centralised analysis by a 
core laboratory. Furthermore, clinically indicated revascu-
larisation was used as a component in the composite clini-
cal endpoint rather than target lesion revascularisation 
based on the low event rates to allow for meaningful statis-
tical analysis. Low patient numbers obviated a meaningful 
interpretation of data on biomarker concentrations in 
NSTEMI patients. Patients with unstable angina were not 
included in the study due to the low patient number (62 
patients) and due to the fact that the prevalence of coronary 
thrombus was previously described to be very low in unsta-
ble angina patients.22
Conclusion
Based on real-world data derived from the current analysis 
of the SPUM–ACS cohort, patients with STEMI and 
NSTEMI showed no difference in procedural success 
when treated by TA with PCI, compared with PCI alone, as 
assessed by TIMI flow. Furthermore, serial hsTnT levels, 
as a measure of infarct size, and short and long-term adju-
dicated clinical events were similar in patients treated by 
TA with PCI, compared with PCI alone.
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